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co-receptor CD14 (sCD14) in plasma from R. conorii-infected patients. The clinical data was 48 supplementsupplemented with ex vivo experiments where the cytokine response was 49 characterized in human whole blood stimulated with R. conorii. Complement activation 50 markers at the level of C3 (C3bc, C3bBbP) and terminal pathway activation (sC5b-9), as well 51 as sCD14, were markedly elevated (p<0.01 for all), and closely correlated (p<0.05 for all), in 52 patients at admission as compared to healthy matched controls. All tested markers were 53 significantly reduced to baseline values at time of follow-up. R. conorii incubated in human 54 whole blood was shown to trigger complement activation accompanied with release of the 55 inflammatory cytokines IL-1β, IL-6, IL-8 and TNF. Whereas inhibition of either C3 or CD14 56 had only minor effect of released cytokines, combined inhibition of C3 and CD14 resulted in 57 significant reduction, virtually to baseline levels, of the four cytokines (p<0.05 for all). Our 58
Introduction 63
The clinical spectrum of spotted fever group (SFG) rickettsioses varies in severity from mild 64 to potentially lethal disease with systemic multi-organ involvement such as in some cases of 65
Mediterranean spotted fever (MSF) caused by R. conorii. The pathophysiological hallmark 66 of SFG rickettsioses comprises infection of endothelial cells and subsequent perivascular 67 infiltration of T cells and monocytes with vascular inflammation and increased microvascular 68 permeability and in some cases, edema in vital organs (e.g. lung and brain) as consequences 69 ([1, 2) ]. Although several inflammatory mediators have been suggested to play a role in the 70 pathogenesis of SFG, the characterization of the different actors is still not fulfilled. 71
The complement system consists of more than 50 membrane-bound and soluble 72 proteins, comprising factors for activation, regulation and effector functions (3). [3] . 73 Activation can be initiated via three different pathways, typically triggered by antigen-74 antibody complexes by the classical pathway (CP), certain carbohydrate patterns by the lectin 75 pathway (LP) and principally all surfaces lacking proper regulatory molecules by the 76 alternative pathway (AP), thereby sensing a broad range of structures. An initiated response is 77 in general multiplied via a potent amplification loop within the AP, responsible for a major 78 part of the antimicrobial effects (i.e. generation of anaphylatoxins, opsonisation and 79 complement-mediated lysis) (4). [4] . A potent complement response contributes to elimination 80 of invading microbes, but an excessive and inappropriate response can instead lead to 81 complement driven tissue damage and organ dysfunction as sometimes seen in septicaemia 82 ([5, 6) ]. 83 CD14 is a pattern recognition receptor which acts as a co-receptor in conjunction with 84 multiple of the Toll-like receptors (TLRs), e.g. the lipopolysaccharide (LPS)-sensing TLR4 85 ([7, 8) ]. CD14 is primarily expressed at the surface of monocytes and macrophages, whereas a 86 soluble form (sCD14) is present in plasma and serum ([9) ].. Both membrane bound and 87 sCD14 are functionally active [10] . Several inflammatory stimuli can induce elevation of 88 sCD14 by promoting increased shedding of membrane CD14 and activate release of 89 intracellularly stored CD14 from monocytes (10), [11] , and measuring sCD14 levels has a 90 prognostic value in e.g. septicaemia (11) [12] . 91
Although complement activation and CD14 play an important role in the pathogenesis 92 of gramGram negative bacterial infection such as E. coli sepsis (12, [13), 14] , to the best of 93 our knowledge, no studies have ever investigated these two mediator systems in the context of 94 clinical R. conorii infection. While some experimental studies suggest that R. conorii is 95 resistant to complement-mediated killing (14, [15) , 16], there are no studies on the degree of 96 complement activation in clinical R. conorii. Moreover, the literature is devoid of data on the 97 regulation of CD14 in human R. conorii infection. 98
We hypothesized that complement and CD14 could play an important role in 99 mediating the inflammatory response in human R. conorii infection. This hypothesis was 100 explored by (i) measuring complement activation markers and sCD14 in patients with R. were blocked using a mouse anti-human CD14 F(ab´) 2 (clone 18D11) and an irrelevant mouse 149 F(ab´) 2 (from mouse IgG1, clone BH1) was used as control (both from Diatec AS, Oslo, 150 Norway). 151
152

Ex vivo whole blood incubations 153
Whole blood incubations were performed using the lepirudin based human whole blood 154 model described in detail previously (19) . [21] . Whole blood was obtained from nonimmune 155 8 healthy adult volunteers who had received no medication for at least 10 days. Blood was 156 drawn from an antecubital vein into 4.5 mL sterile polypropylene cryotubes (Nalgene NUNC, 157
Roskilde, Denmark) containing the thrombin specific inhibitor lepirudin (Refludan; Pharmion 158 ApS, Copenhagen, Denmark) at a final concentration of 50 g/mL. Lepirudin was used as 159 anticoagulant in all ex vivo experiments. The inflammatory response in whole blood was 160 studied by incubating R. conorii (1x10 5 bacteria/mL) in 1.8 mL round-bottom sterile 161 polypropylene NUNC cryotubes (Nalgene NUNC) on rotation for two or four hours at 37°C. 162 The complement activation products C1rs-C1INH, C4bc, C3bc, C3bBbP and, the soluble 174 terminal complement complex (sC5b-9) and C1rs-C1INH were analysed in EDTA-plasma 175 samples using enzyme-linked immunosorbent assays (ELISAs) as described in detail 176 previously (20). [22] . Briefly, the assays were either based on monoclonal antibodies detecting 177 neo-epitopes exposed after activation (C4bc, C3bc, sC5b-9) or complex formation (C1rs-178 C1INH) or pair of antibodies detecting complex formed between single components upon 179 activation (C3bBbP), thus specifically measuring only components exposed or formed upon 180 9 activation. The amount of activation products present is related to an international standard 181 defined to contain 1000 complement arbitrary units (CAU)/mL (20). [22] . sCD14 was 182 analysed in serum samples using the HK320 human sCD14 kit (Hycult, Uden, the 183 Netherlands). 184
185
Cytokine assays 186
Plasma samples from whole blood ex vivo incubated with R. conorii were analysed using a All data was compiled using Prism version 6.0 (GraphPad Software, La Jolla CA). For the 206 patient data, differences between patients at admission were compared against controls and 207 patients at follow-up with the Kruskal-Wallis test (C3bc, C3bBbP, sCD14) or 208 between admission and follow-up using the Mann-Whitney test (C1rs-C1INH, C4bc) when 209 lacking reliable control data.. Correlations between activation parameters were analysed using 210
Spearman's rank order correlation. Data from the ex vivo experiments were initially tested for 211 statistical difference between whole blood with R. conorii and the buffer controls using paired 212 t-test (consistent differences: sC5b-9, IL-8; consistent ratios: IL-1β, IL-6, TNF). If 213 significantly separated (p<0.05). The), the R. conorii-samples were further compared to R. 214 conorii-whole blood supplemented with inhibitors using repeated measures one-way ANOVA 215 followed by Dunnett´s multiple comparisons test. 216
217
Results
218
In vivo complement activation during R. conorii infection 219
Plasma samples from 36 patients with confirmed MSF were analysed for fivefour different 220 complement activation markers reflecting activation at different stages of the complement 221 system. On admission, three of these markers were significantly increased as compared to the 222 matched healthy controls (n=9) (Fig. 1) . Thus, C3bc (p<0.001), a marker of C3-activation, 223 and the alternative pathway C3-convertase (C3bBbP) (p<0.001), were both significantly 224 increased on admission, and dropped to normal levels at follow-up. Importantly, the terminal 225 complement complex (sC5b-9) was also significantly increased at admission (p<0.0001) and 226 significantly lowered at follow-up indicating that the complement cascade was activated to 227 the very end, including release of C5a, in patients with MSF. All three markers showed strong 228 internal correlation, C3bc correlated to C3bBbP (r=0.84, p<0.0001) and to sC5b-9 (r=0.67, 229 p<0.0001) and C3bBbP correlated to sC5b-9 (r=0.71, p<0.0001). We have established 230 reference values for these assays (20),We have established reference values for these assays 231 [22] , and all the healthy controls and patients at follow-up presented levels within the range of 232 the reference values for respective assays. 233
Activation markers C1rs-C1INH and C4bc, representing activation of the classical 234 pathways and C4bc in addition reflecting activation of the lectin pathway, were both 235 markedly elevated on admission as compared to reference values for each assay, and were 236 significantly lowered at follow-up (C1rs-C1INH: p<0.01, C4bc: p<0.05) (Fig. 2) . For these 237 two assays, the samples from the healthy control population were above the stated reference 238 values, and therefore not included in the analyses. Positive significant correlation was found 239 between C1rs-C1INH and C4bc (r=0.54, p<0.01) and for C4bc against C3bc (r=0.42, p<0.05) 240
but not against other complement activation markers. 241
We then examined whether the classical pathway could be the initial trigger of the 242 complement activation observed. For this purpose we use the C1rs-C1INH assay. Patients at 243 admission had markedly elevated C1rs-C1INH complexes than at follow-up (p<0.05) (Fig.  244   1D) . The control population also had higher levels of C1rs-C1INH complexes than the 245 reference range, and these did not differ from the values seen in patients at admittance. 246 247
In vivo sCD14 during R. conorii infection 248
At admission serum levels of sCD14 in patients with confirmed R. conorii infection were 249 significantly raised as compared to the levels in matched healthy controls (p<0.01), and at 250 time of follow-up, sCD14 had returned to normal (Fig. 32) . Levels of sCD14 showed 251 significant positive correlation to fourall of the complement activation markers: C1rs-C1INH 252 (r=0.59, p<0.01), C3bc (r=0.42, p<0.05), C3bBbP (r=0.39, p<0.05) and sC5b-9 (r=0.61, 253 p<0.001), but not against C4bc (r=0.24, p=0.21).). 254
255
Ex vivo whole blood complement activation and cytokine release in response to R. conorii 256 R. conorii was incubated in human whole blood ex vivo, after which complement activation 257 was measured as generation of sC5b-9 after two hours, and the levels of 27 different 258 cytokines were analysed after 4 hours by multiplex technology. R. conorii induced significant 259 complement activation (p<0.01) as compared to the buffer control (Fig 4A3A) . When 260 analysing a broad array of cytokines, nine out of 27 were found increased 2-fold or more in R. 261 conorii as compared to the buffer control (Fig. 4B3B) . The overall cytokine profile was 262 strongly balanced towards an inflammatory state, exhibiting TNFIL-1β, IL-6 and, IL-8 and 263
IL-1β asTNF among the top fourmarkedly induced analytes measured as highest 264 concentrations upon stimulation with R. conorii. 265 266 13
Modulation of R. conorii-induced inflammation ex vivo by targeting C3 and CD14 267
R. conorii-induced inflammation ex vivo, evaluated as release of the four of the most potent 268 cytokine responders, i.e., IL-1β, IL-6, IL-8 and TNF (cfr. Fig 4B3B) , was then targeted by 269 applying inhibitors directed against the central complement component C3, and the TLR-co-270 receptor CD14. As in the first experiment, R. conorii induced significant increase in IL-1β, 271 IL-6, IL-8 and TNF (all p<0.001) compared to the buffer control (Fig. 54) . Targeting of C3 272 alone significantly lowered the level of IL-8 only (p<0.05), whereas CD14 inhibition alone 273 did not inhibit any of the four cytokines (. Fig. 5 ). In contrast, targeting of C3 and CD14 in 274 combination resulted in significant reduction of all the four analytes with a mean attenuation 275 by 75% for IL-1β (p<0.05), by 84% for IL-6 (p<0.0001), by 83% for IL-8 (p<0.001) and by 276 70% for TNF (p<0.01) (Fig 54) . (15, 21) [16, 23] . In the present in vivo study we 296 thoroughly investigated complement activation by measuring activation markers at different 297 levels of the system and we could, for the first time, show enhanced complement activation in 298 MSF patients with increased levels of the terminal complement complex, sC5b-9, as the 299 major finding. Markersand markers reflecting C3 (alternative pathway activation, i.e. C3bc 300 and C3bBbP) and C4 activation (C4bc) were also markedly elevated in patients in addition. 301
The alternative pathway can be activated directly by a foreign surface or be amplified 302 irrespective of which initial pathway that is triggered. We measured the C1rs-C1INH 303 15 complexes to investigate whether the classical pathway specific C1rs-C1INH complex which 304 was could be activated. There was indeed a markedly and significantly elevated in patients on 305 admission as compared to higher level of C1rs-C1INH at admittance than at follow-up which 306 indicate that complement activation, at least in some patients, was triggered by the , 307 suggesting classical pathway. activation, but these data should be interpreted with caution due 308 to a higher level in the control population than expected. Thus, althoughthough in vitro 309 studies suggest that R. conorii could bind factor H and thereby avoid complement-mediated 310 clearance this mechanism seems not to be operatingfully applicable in vivo in MSF patients. 311
Our ex vivo studies suggest that R. conorii itself can activate the complement system to the 312 very end (i.e. generation of C5b-9). If R. conorii binds vitronectin from host plasma and 313 thereby counteract C5b-9 mediated killing of the bacteria could, the enhanced complement 314 activation in MSF patients could have harmful effect on the host through induction of 315 bystander tissue damage and inflammation. Still, with the plethora of different strategies that 316 microbes have developed to evade complement recognition and clearance, one can speculate 317 that rickettsial hijacking of complement regulators could prolong bacterial lifetime in blood 318 long enough to enable intracellular escape. Nevertheless, the highly significant sC5b-9 and 319 C3-activation found in patients rule out that R. conorii infection occur without complement 320 activation. 321
Increased serum level of sCD14 is primarily thought to reflect enhanced activation of 322 monocytes but sCD14 can also could be derived from neutrophils (10). [11] . Monocyte 323 activation has been reported during R. conorii infection, contributing to the adherence of 324 monocytes to the activated endothelium in R. conorii-infected endothelial cells (22) [24] . Our 325 finding in the present study with increased serum levels of sCD14 in MSF patients on 326 admission to the hospital, further support that monocyte activation is a characteristic of these 327 patients. sCD14 was significantly correlated with sC5b-9 levels, suggesting concurrent 328 activation of both complement and monocytes upon infection. 329
The pathophysiological significance of enhanced complement activation in MSF 330 patients is at present not clear. However, our ex vivo findings suggest that activation of the 331 complement cascade could contribute to R. conorii-mediated inflammation. Exposure of 332 human whole blood to R. conorii induced elevation of several inflammatory cytokines, of 333 which IL-1β, IL-6, IL-8 and TNF were among the most abundant. Inhibition of C3 attenuated 334 R. conorii-mediated IL-8 release, potentially attributed to C5 dependent mechanisms (i.e. C5a 335 and C5b-9). Moreover, when combined with CD14 inhibition, C3 inhibition markedly 336
attenuated the response of all tested inflammatory cytokines (i.e., IL-1, IL-6 and TNF in 337 addition to more profound inhibition of IL-8).Although blockade of CD14 alone did not lower 338 any of the four cytokines, anti-CD14 enhanced the inhibitory effects seen when C3 was 339 blocked. In fact, the combined C3 and CD14 inhibition was the only regimen that 340 significantly reduced rickettsia-induced release of all four cytokines. IL-1β was statistically 341 increased by anti-CD14 alone. The reason for this is uncertain, but most likely due to 342 methodological type I error, since it was not seen for any of the other cytokines, and in 343 particular since anti-CD14 potentiated the inhibitory effect of C3 to significant level, close to 344 the background, as seen for the other cytokines as well. CD14 is a promiscuous protein 345 primarily known as an accessory molecule facilitating LPS transfer from LPS-binding protein 346 to TLR4-MD2 complexes. Recent studies indicate considerable cross-talk between 347 complement and TLR4 activation, and we have shown reduced inflammation upon combined 348 targeting of CD14 and complement in various experimental models, even when the 349 inflammation is predominantly LPS-induced and therefore CD14 dependent (12, 23) [13, 25] . 350
Our findings in the present study suggest that similar mechanisms could be operating in R. 351 conorii infection. 352
The present study has some limitations such as a low number of patients during 353 follow-up, and although we in our lab have established reference values for the actual 354 complement parameters, the numbers of healthy controls were rather low. On the other side, a 355 broad spectrum of complement activation markers were analysed all showing the same 356 pattern. 357
In conclusion, we demonstrate enhanced activation of the complement cascade and 358 increased sCD14 in MSF patients, and our ex vivo findings suggest that targeted therapy 359 against complement activation and CD14 could be of interest in severe R. conorii infection. 360 361
